Trial Profile
A comparative bioavailability study of new formulation of Ht-3951 with the refernece formulation in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Apr 2017
Price :
$35
*
At a glance
- Drugs HT 3951 (Primary)
- Indications Stroke
- Focus Pharmacokinetics
- 05 Apr 2017 New trial record
- 18 Mar 2017 Results presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics